https://doi.org/10.4081/hmr.v1i8.290

Bortezomib in lymphoma

Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
Published: June 3, 2009
Abstract Views: 119
PDF: 134
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

A Goy
support@pagepress.org
Bortezomib, the first of its class of new agents called proteasome inhibitors, was approved by the FDA initially as third line therapy in multiple myeloma (MM) in May 2003 and added early 2005 as second line option in this disease. In parallel activity of bortezomib has been shown in a variety of lymphomas especially in mantle cell and follicular lymphoma subtypes. Though inhibitors of the proteasome can be considered as targeted agents (i.e. affecting a discrete enzymatic subunit in the UPP pathway), the antitumor effect of proteasome inhibitors results from the disruption of multiple pathways in cancer cells (cell cycle, cell survival, growth and differentiation) as well as on microenvironment (adhesion molecules and angiogenesis).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Goy, A. (2009). Bortezomib in lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.290
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).